ANAB vs. PHVS, LYEL, GHRS, MLYS, AVBP, CALT, ZYME, PHAT, PHAR, and ABUS
Should you be buying AnaptysBio stock or one of its competitors? The main competitors of AnaptysBio include Pharvaris (PHVS), Lyell Immunopharma (LYEL), GH Research (GHRS), Mineralys Therapeutics (MLYS), ArriVent BioPharma (AVBP), Calliditas Therapeutics AB (publ) (CALT), Zymeworks (ZYME), Phathom Pharmaceuticals (PHAT), Pharming Group (PHAR), and Arbutus Biopharma (ABUS). These companies are all part of the "pharmaceutical preparations" industry.
Pharvaris (NASDAQ:PHVS) and AnaptysBio (NASDAQ:ANAB) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, community ranking, valuation, media sentiment, earnings, analyst recommendations and profitability.
Pharvaris presently has a consensus target price of $31.50, indicating a potential upside of 54.19%. AnaptysBio has a consensus target price of $46.38, indicating a potential upside of 94.85%. Given Pharvaris' stronger consensus rating and higher possible upside, analysts clearly believe AnaptysBio is more favorable than Pharvaris.
In the previous week, AnaptysBio had 8 more articles in the media than Pharvaris. MarketBeat recorded 10 mentions for AnaptysBio and 2 mentions for Pharvaris. AnaptysBio's average media sentiment score of 1.49 beat Pharvaris' score of 0.85 indicating that Pharvaris is being referred to more favorably in the media.
AnaptysBio received 318 more outperform votes than Pharvaris when rated by MarketBeat users. Likewise, 65.61% of users gave AnaptysBio an outperform vote while only 64.71% of users gave Pharvaris an outperform vote.
Pharvaris has higher earnings, but lower revenue than AnaptysBio. Pharvaris is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks.
Pharvaris has a beta of -3.02, suggesting that its stock price is 402% less volatile than the S&P 500. Comparatively, AnaptysBio has a beta of -0.32, suggesting that its stock price is 132% less volatile than the S&P 500.
Pharvaris has a net margin of 0.00% compared to Pharvaris' net margin of -711.17%. AnaptysBio's return on equity of -39.67% beat Pharvaris' return on equity.
Summary
AnaptysBio beats Pharvaris on 10 of the 15 factors compared between the two stocks.
Get AnaptysBio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ANAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
AnaptysBio Competitors List
Related Companies and Tools
